Literature DB >> 9596110

The effects of static charge in spacer devices on glucocorticosteroid aerosol deposition in asthmatic patients.

C J Kenyon1, L Thorsson, L Borgström, S P Newman.   

Abstract

Electrostatic charge in plastic spacer devices has been shown in vitro to reduce delivery of asthma medications intended for inhalation, but the effect of static charge on in vivo drug deposition is unknown. A six-way randomized crossover study was conducted in 10 mild asthmatic patients. Two plastic spacers (Nebuhaler and Volumatic) and one metal spacer (Nebuchamber) were tested. The spacers were used either "primed" or "unprimed". Priming was performed by firing 20 doses of placebo aerosol into a new spacer, hence coating the inner surface with surfactant and minimizing static charge. Unprimed spacers were new and were not treated. Pressurized aerosol canisters delivering budesonide (200 microg Pulmicort) were radiolabelled with the radionuclide 99mTc and lung deposition was measured by gamma scintigraphy. The radiolabel was shown to be a valid marker for the drug substance prior to the clinical phase of the study. Priming significantly increased mean whole lung deposition following inhalation from plastic spacers (Nebuhaler primed 37.7% and unprimed 26.7%, p=0.01; Volumatic primed 32.0% and unprimed 22.1%, p=0.02). Priming had no effect on the mean whole lung deposition following inhalation from the Nebuchamber (primed 33.5% and unprimed 32.9%). Lung deposition in vivo from plastic spacer devices will vary according to the electrostatic charge on the spacer walls. Priming reduces retention of drug on plastic spacer devices and increases lung deposition. Metal spacers are not susceptible to static charge, which should result in more predictable lung deposition.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9596110

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  14 in total

1.  Randomised controlled study of clinical efficacy of spacer therapy in asthma with regard to electrostatic charge.

Authors:  E Dompeling; A M Oudesluys-Murphy; H M Janssens; W Hop; J G Brinkman; R N Sukhai; J C de Jongste
Journal:  Arch Dis Child       Date:  2001-02       Impact factor: 3.791

2.  Reducing electrostatic charge on spacer devices and bronchodilator response.

Authors:  J H Wildhaber; G W Waterer; G L Hall; Q A Summers
Journal:  Br J Clin Pharmacol       Date:  2000-09       Impact factor: 4.335

3.  Bioavailability of inhaled fluticasone propionate via chambers/masks in young children.

Authors:  K Blake; R Mehta; T Spencer; R L Kunka; L Hendeles
Journal:  Eur Respir J       Date:  2011-09-20       Impact factor: 16.671

Review 4.  Deposition and effects of inhaled corticosteroids.

Authors:  Stephen P Newman
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 5.  Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.

Authors:  L P Boulet; A Becker; D Bérubé; R Beveridge; P Ernst
Journal:  CMAJ       Date:  1999-11-30       Impact factor: 8.262

Review 6.  Spacer devices for metered dose inhalers.

Authors:  Stephen P Newman
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

7.  In vivo comparison of the relative systemic bioavailability of fluticasone propionate from three anti-static spacers and a metered dose inhaler.

Authors:  Arun Nair; Daniel Menzies; Pippa Hopkinson; Lesley McFarlane; Brian J Lipworth
Journal:  Br J Clin Pharmacol       Date:  2009-02-09       Impact factor: 4.335

8.  Controller Inhalers: Overview of Devices, Instructions for Use, Errors, and Interventions to Improve Technique.

Authors:  Patrick K Gleeson; Scott Feldman; Andrea J Apter
Journal:  J Allergy Clin Immunol Pract       Date:  2020-03-12

Review 9.  Use of inhaler devices in pediatric asthma.

Authors:  Fernando Maria De Benedictis; David Selvaggio
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 10.  Budesonide at different doses for chronic asthma.

Authors:  N Adams; J Bestall; P W Jones
Journal:  Cochrane Database Syst Rev       Date:  2001
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.